Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies

References

• Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol. 2009;157(1):9–19. doi:10.1111/j.1365-2249.2009.03912.x.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Patel R, Bock M, Polotti CF, Elsamra S. Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma. Expert Opin Drug Metab Toxicol. 2017;13(2):225–232. doi:10.1080/17425255.2017.1277204.
   PubMed Web of Science ®Google Scholar
• Shultz D. Three Drugs Approved for Urothelial Carcinoma by FDA. Cancer Discov. 2017;7(7):659–660. doi:10.1158/2159-8290.CD-NB2017-071.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Flaherty CR, Postow MA. Checkpoint blockade for the treatment of advanced melanoma. Cancer Treat Res. 2016;167:231–250. doi:10.1007/978-3-319-22539-5_9.
   PubMedGoogle Scholar
• Lee CS, Cragg M, Glennie M, Johnson P. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol. 2013;76(2):233–247. doi:10.1111/bcp.12164.
   PubMed Web of Science ®Google Scholar
• Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, et al. Trial watch: immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology. 2015; 4(4):e1008814. doi:10.1080/2162402X.2015.1008814.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. LAG-3, TIM-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004. doi:10.1016/j.immuni.2016.05.001.
   PubMed Web of Science ®Google Scholar
• Goldberg MV, Drake CG. LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol. 2011;344::269–278. doi:10.1007/82_2010_114.
   PubMed Web of Science ®Google Scholar
• Huang C-T, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503–513. doi:10.1016/j.immuni.2004.08.010.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003;4(7):670–679. doi:10.1038/ni944.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242. doi:10.1038/nri3405.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Pastor F, Rodriguez A, Perez-Gracia JL, Rodriguez-Ruiz ME, Jure-Kunkel M. Agonists of costimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol. 2015;42(4):640–655. doi:10.1053/j.seminoncol.2015.05.014.
   PubMed Web of Science ®Google Scholar
• Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol. 2002;168(10):4897–4906. doi:10.4049/jimmunol.168.10.4897.
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561–584. doi:10.1038/nrd4591.
   PubMed Web of Science ®Google Scholar
• Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270–1271. doi:10.1056/NEJMc1509660.
   PubMed Web of Science ®Google Scholar
• Maçon-Lemaître L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology. 2005;115(2):170–178. doi:10.1111/j.1365-2567.2005.02145.x.
   PubMed Web of Science ®Google Scholar
• Wang C, Thudium KB, Han M, Wang X-T, Huang H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846–856. doi:10.1158/2326-6066.CIR-14-0040.
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Johnston RJ, Lu L-S, Han M, Thudium K, Yao D, Quigley M, Valle J, Wang C, et al. Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology. PLoS One. 2016;11(11):e0161779. doi:10.1371/journal.pone.0161779.
   PubMed Web of Science ®Google Scholar
• Wang S, Campos J, Gallotta M, Gong M, Crain C, Naik E, Coffman RL, Guiducci C. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci USA. 2016;113(46):E7240–E7249. doi:10.1073/pnas.1608555113.
   PubMed Web of Science ®Google Scholar
• Monaci P, Luzzago A, Santini C, De Pra A, Arcuri M, Magistri F, Bellini A, Ansuini H, Ambrosio M, Ammendola V, et al. Differential screening of phage-ab libraries by oligonucleotide microarray technology. PLoS One. 2008;3(1):e1508. doi:10.1371/journal.pone.0001508.
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462. doi:10.1080/2162402X.2016.1163462.
   PubMed Web of Science ®Google Scholar
• Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16(3):131–144. doi:10.1038/nrc.2016.14.
   PubMed Web of Science ®Google Scholar
• Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci USA. 2011;108(1):266–271. doi:10.1073/pnas.1016791108.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016;11(7):e0160221. doi:10.1371/journal.pone.0160221.
   PubMed Web of Science ®Google Scholar
• De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, D’Alessio G. A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res. 2002;8(6):1710–1719. PMID: 12060608.
   PubMed Web of Science ®Google Scholar
• Sasso E, Paciello R, D’Auria F, Riccio G, Froechlich G, Cortese R, Nicosia A, De Lorenzo C, Zambrano N. One-step recovery of scfv clones from high throughput sequencing-based screening of phage display libraries challenged to cells expressing native Claudin-1. BioMed Res Int. 2015;2015::703213. doi:10.1155/2015/703213.
   PubMedGoogle Scholar
• Paciello R, Urbanowicz RA, Riccio G, Sasso E, McClure CP, Zambrano N, Ball JK, Cortese R, Nicosia A, De Lorenzo C. Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. J Gen Virol. 2016;97(1):82–94. doi:10.1099/jgv.0.000330.
   PubMedGoogle Scholar
• Sasso E, Latino D, Froechlich G, Succoio M, Passariello M, De Lorenzo C, Nicosia A, Zambrano N. A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells. mAbs. 2018;10(5):730–737. doi:10.1080/19420862.2018.1463945.
   PubMed Web of Science ®Google Scholar